Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with CetuximabReport as inadecuate




Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab - Download this document for free, or read online. Document in PDF available to download.

Drugs in R and D

, Volume 11, Issue 4, pp 317–326

A Meta-AnalysisFirst Online: 27 November 2012

Abstract

Background and Aim: Neutropenia is a serious adverse event for patients who are treated with cetuximab, an inhibitor of endothelial growth factor receptor. However, there is no consistent result of the relationship between cetuximab and neutropenia in randomized controlled trials RCTs. We did a systematic review and meta-analysis of published RCTs to assess the overall risk of neutropenia associated with cetuximab.

Methods: PubMed, Cochrane Central Register of Controlled Trials, EMBASE, and American Society of Clinical Oncology conferences were searched for relevant RCTs. Quantitative and qualitative analyses were carried out to evaluate the association between neutropenia and cetuximab. Both the fixed-effect model and random-effects model were used.

Results: A total of 7186 patients with a variety of advanced cancers from 14 trials were included in our analysis. The overall incidence of neutropenia in patients receiving cetuximab was 33% 95% CI 26, 43. Patients treated with cetuximab had a significantly increased risk of neutropenia compared with patients treated with control medication, with a relative risk RR of 1.12 95% CI 1.05, 1.19; fixed-effect model. Risk varied with tumor type. Higher risks were observed in patients with colorectal carcinoma RR 1.17; 95% CI 1.04, 1.32; fixed-effect model and non-small cell lung cancer RR 1.07; 95% CI 0.99, 1.16; fixed-effect model.

Conclusion: Cetuximab is associated with a significant risk of neutropenia in patients with advanced cancer receiving concurrent chemotherapy.

Download fulltext PDF



Author: Long Wang - Yi-zhi Chen - Duo Shi - Xue-yin Shi - Zui Zou - Jian-hua Zhao

Source: https://link.springer.com/







Related documents